{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["135(19)"],"submitter":["Yin S"],"pubmed_abstract":["Background
Although ABO-incompatible (ABOi) kidney transplantation (KT) has been performed successfully, a standard preconditioning regimen has not been established. Based on the initial antidonor ABO antibody titers, an individualized preconditioning regimen is developed, and this study explored the efficacy and safety of the regimen.Methods
From September 1, 2014, to September 1, 2020, we performed 1668 consecutive living-donor KTs, including 100 ABOi and 1568 ABO-compatible (ABOc) KTs. ABOi KT recipients (KTRs) with a lower antibody titer (≤1:8) were administered oral immunosuppressive drugs (OIs) before KT, while patients with a medium titer (1:16) received OIs plus antibody-removal therapy (plasma exchange/double-filtration plasmapheresis), patients with a higher titer"],"journal":["Chinese medical journal"],"pagination":["2303-2310"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9771334"],"repository":["biostudies-literature"],"pubmed_title":["Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation."],"pmcid":["PMC9771334"],"pubmed_authors":["Zhang F","Yang Y","Fan Y","Huang Z","Lin T","Yin S","Song T","Wang X","Tan Q"],"additional_accession":[]},"is_claimable":false,"name":"Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation.","description":"Background
Although ABO-incompatible (ABOi) kidney transplantation (KT) has been performed successfully, a standard preconditioning regimen has not been established. Based on the initial antidonor ABO antibody titers, an individualized preconditioning regimen is developed, and this study explored the efficacy and safety of the regimen.Methods
From September 1, 2014, to September 1, 2020, we performed 1668 consecutive living-donor KTs, including 100 ABOi and 1568 ABO-compatible (ABOc) KTs. ABOi KT recipients (KTRs) with a lower antibody titer (≤1:8) were administered oral immunosuppressive drugs (OIs) before KT, while patients with a medium titer (1:16) received OIs plus antibody-removal therapy (plasma exchange/double-filtration plasmapheresis), patients with a higher titer","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-26T09:43:53.244Z","creation":"2025-04-06T13:09:20.228Z"},"accession":"S-EPMC9771334","cross_references":{"pubmed":["36103981"],"doi":["10.1097/CM9.0000000000002138"]}}